Predicting progression of IgA nephropathy: New clinical progression risk score

PLoS ONE

Volumn 7, Issue 6, 2012, Pages

  Xie, Jingyuan ^a,b   Kiryluk, Krzysztof ^b   Wang, Weiming ^a   Wang, Zhaohui ^a   Guo, Shanmai ^a   Shen, Pingyan ^a   Ren, Hong ^a   Pan, Xiaoxia ^a   Chen, Xiaonong ^a   Zhang, Wen ^a   Li, Xiao ^a   Shi, Hao ^a   Li, Yifu ^b   Gharavi, Ali G ^b   Chen, Nan ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b Columbia University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOCORTICOID; HEMOGLOBIN; IMMUNOGLOBULIN A;

ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; CHINESE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; IMMUNOGLOBULIN A NEPHROPATHY; INTERMETHOD COMPARISON; KIDNEY BIOPSY; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OUTCOME ASSESSMENT; PREDICTION; PROPORTIONAL HAZARDS MODEL; RECEIVER OPERATING CHARACTERISTIC; RENAL REPLACEMENT THERAPY; RISK ASSESSMENT; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; SYSTOLIC BLOOD PRESSURE;

ADULT; DISEASE PROGRESSION; FEMALE; GLOMERULONEPHRITIS, IGA; HUMANS; MALE; MIDDLE AGED;

EID: 84862261279     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0038904     Document Type: Article

References (38)

1. Levy M, Berger J, (1988) Worldwide perspective of IgA nephropathy. Am J Kidney Dis 12: 340-347.
2. Radford MG Jr, Donadio JV Jr, Bergstralh EJ, Grande JP, (1997) Predicting renal outcome in IgA nephropathy. J Am Soc Nephrol 8: 199-207.
3. D'Amico G, Colasanti G, Barbiano di Belgioioso G, Fellin G, Ragni A, et al. (1987) Long-term follow-up of IgA mesangial nephropathy: clinico-histological study in 374 patients. Semin Nephrol 7: 355-358.
4. Donadio JV, Grande JP, (2002) IgA nephropathy. N Engl J Med 347: 738-748.
5. Li L, (1996) End-stage renal disease in China. Kidney Int 49: 287-301.
6. Koyama A, Igarashi M, Kobayashi M, (1997) Natural history and risk factors for immunoglobulin A nephropathy in Japan. Research Group on Progressive Renal Diseases. Am J Kidney Dis 29: 526-532.
7. Li PK, Ho KK, Szeto CC, Yu L, Lai FM, (2002) Prognostic indicators of IgA nephropathy in the Chinese-clinical and pathological perspectives. Nephrol Dial Transplant 17: 64-69.
8. Lv J, Zhang H, Zhou Y, Li G, Zou W, et al. (2008) Natural history of immunoglobulin A nephropathy and predictive factors of prognosis: a long-term follow up of 204 cases in China. Nephrology 13: 242-246.
9. Goto M, Wakai K, Kawamura T, Ando M, Endoh M, et al. (2009) A scoring system to predict renal outcome in IgA nephropathy: a nationwide 10-year prospective cohort study. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association- European Renal Association 24: 3068-3074.
10. Berthoux F, Mohey H, Laurent B, Mariat C, Afiani A, et al. (2011) Predicting the risk for dialysis or death in IgA nephropathy. Journal of the American Society of Nephrology: JASN 22: 752-761.
11. Donadio JV, Bergstralh EJ, Grande JP, Rademcher DM, (2002) Proteinuria patterns and their association with subsequent end-stage renal disease in IgA nephropathy. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association- European Renal Association 17: 1197-1203.
12. Reich HN, Troyanov S, Scholey JW, Cattran DC, (2007) Remission of proteinuria improves prognosis in IgA nephropathy. Journal of the American Society of Nephrology: JASN 18: 3177-3183.
13. Kaartinen K, Syrjanen J, Porsti I, Hurme M, Harmoinen A, et al. (2008) Inflammatory markers and the progression of IgA glomerulonephritis. Nephrol Dial Transplant 23: 1285-1290.
14. Keane WF, Zhang Z, Lyle PA, Cooper ME, de Zeeuw D, et al. (2006) Risk scores for predicting outcomes in patients with type 2 diabetes and nephropathy: the RENAAL study. Clinical journal of the American Society of Nephrology: CJASN 1: 761-767.
15. Tangri N, Stevens LA, Griffith J, Tighiouart H, Djurdjev O, et al. (2011) A predictive model for progression of chronic kidney disease to kidney failure. JAMA: the journal of the American Medical Association 305: 1553-1559.
16. Ma YC, Zuo L, Chen JH, Luo Q, Yu XQ, et al. (2006) Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. J Am Soc Nephrol 17: 2937-2944.
17. National Kidney Foundation (2002) K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. American journal of kidney diseases: the official journal of the National Kidney Foundation 39: S1-266.
18. Therneau PGaT, (1994) Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 81: 11.
19. Nagelkerke NJD, (1991) A note on a general definition of the coefficient of determination. Biometrika 78: 691-692.
20. Haibe-Kains B, Desmedt C, Sotiriou C, Bontempi G, (2008) A comparative study of survival models for breast cancer prognostication based on microarray data: does a single gene beat them all? Bioinformatics 24: 2200-2208.
21. Sing T, Sander O, Beerenwinkel N, Lengauer T, (2005) ROCR: visualizing classifier performance in R. Bioinformatics 21: 3940-3941.
22. Dupont WD, Plummer WD Jr, (1990) Power and Sample Size Calculations: A Review and Computer Program. Controlled Clinical Trials 11: 116-128.
23. Kiryluk K, Julian BA, Wyatt RJ, Scolari F, Zhang H, et al. (2010) Genetic studies of IgA nephropathy: past, present, and future. Pediatric nephrology 25: 2257-2268.
24. Mohanram A, Zhang Z, Shahinfar S, Keane WF, Brenner BM, et al. (2004) Anemia and end-stage renal disease in patients with type 2 diabetes and nephropathy. Kidney Int 66: 1131-1138.
25. Staples AO, Greenbaum LA, Smith JM, Gipson DS, Filler G, et al. (2010) Association between clinical risk factors and progression of chronic kidney disease in children. Clinical journal of the American Society of Nephrology: CJASN 5: 2172-2179.
26. Yokoyama H, Tomonaga O, Hirayama M, Ishii A, Takeda M, et al. (1997) Predictors of the progression of diabetic nephropathy and the beneficial effect of angiotensin-converting enzyme inhibitors in NIDDM patients. Diabetologia 40: 405-411.
27. Keane WF, Brenner BM, de Zeeuw D, Grunfeld JP, McGill J, et al. (2003) The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study. Kidney international 63: 1499-1507.
28. Leehey DJ, Kramer HJ, Daoud TM, Chatha MP, Isreb MA, (2005) Progression of kidney disease in type 2 diabetes- beyond blood pressure control: an observational study. BMC Nephrol 6: 8.
29. Fox CS, Larson MG, Leip EP, Culleton B, Wilson PW, et al. (2004) Predictors of new-onset kidney disease in a community-based population. JAMA: the journal of the American Medical Association 291: 844-850.
30. Retnakaran R, Cull CA, Thorne KI, Adler AI, Holman RR, (2006) Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74. Diabetes 55: 1832-1839.
31. Hunsicker LG, Adler S, Caggiula A, England BK, Greene T, et al. (1997) Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study. Kidney Int 51: 1908-1919.
32. Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, et al. (1994) The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med 330: 877-884.
33. Bartosik LP, Lajoie G, Sugar L, Cattran DC, (2001) Predicting progression in IgA nephropathy. American journal of kidney diseases: the official journal of the National Kidney Foundation 38: 728-735.
34. Mackinnon B, Fraser EP, Cattran DC, Fox JG, Geddes CC, (2008) Validation of the Toronto formula to predict progression in IgA nephropathy. Nephron Clinical practice 109: c148-153.
35. Kiryluk K, Moldoveanu Z, Sanders JT, Eison TM, Suzuki H, et al. (2011) Aberrant glycosylation of IgA1 is inherited in both pediatric IgA nephropathy and Henoch-Schonlein purpura nephritis. Kidney international 80: 79-87.
36. Moldoveanu Z, Wyatt RJ, Lee JY, Tomana M, Julian BA, et al. (2007) Patients with IgA nephropathy have increased serum galactose-deficient IgA1 levels. Kidney international 71: 1148-1154.
37. Gharavi AG, Kiryluk K, Choi M, Li Y, Hou P, et al. (2011) Genome-wide association study identifies susceptibility loci for IgA nephropathy. Nature genetics 43: 321-327.
38. Cattran DC, Coppo R, Cook HT, Feehally J, Roberts IS, et al. (2009) The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney international 76: 534-545.